Randomised, placebo-controlled study to assess the safety and efficacy of Enterosgel® in the treatment of functional abdominal pain in children and young people (ENTOPIC): study protocol for a clinical trial.
8 affiliations
- 1Enteromed Ltd, 85 Great Portland Street, First Floor, London, W1W 7LT, UK. [email protected].
- 2Paediatric Gastroenterology, Alder Hey Children's NHS Foundation Trust, E Prescot Rd, Liverpool, L14 5AB, UK.
- 3Paediatric Gastroenterology, Bristol Royal Hospital for Children, Upper Maudlin Street, Bristol, BS2 8BJ, UK.
- 4London School of Hygiene and Tropical Medicine, Keppel Street, London, WC1E 7HT, UK.
- 5Enteromed Ltd, 85 Great Portland Street, First Floor, London, W1W 7LT, UK.
- 6Bioline Products S.R.O, Pátkova 831, Libeň, Prague 8, 182 00, Czech Republic.
- 7Paediatric Gastroenterology, Alder Hey Children's NHS Foundation Trust, E Prescot Rd, Liverpool, L14 5AB, UK. [email protected].
- 8Department of Clinical Sciences, Liverpool School of Tropical Medicine, Pembroke Place, Liverpool, L3 5QA, UK. [email protected].
Abstract
Background
Functional abdominal pain disorders (FAPDs) comprise of irritable bowel syndrome, functional dyspepsia, abdominal migraine and functional abdominal pain not otherwise specified. FAPDs are common in children worldwide, decrease health related quality of life, reduce attendance and participation in school and after-school activities similar to children with inflammatory bowel disease, and incur significant health care costs. The aetiology is thought to involve structural and/or functional disruptions in one or more elements of the microbiota-gut-brain axis. Several different treatment approaches are available, reflecting that none is proven to have significant efficacy. The medical device Enterosgel®, a silicon-based intestinal absorbent, adsorbs immune proteins, bacterial breakdown products and bile acids and normalises the intestinal microbiota. Enterosgel® is effective in irritable bowel syndrome with diarrhoea in adults and is available on prescription and over-the-counter. We plan to evaluate the efficacy, tolerability and safety of Enterosgel® in the treatment FAPDs in children and young people.Methods
In a UK two-centre, parallel arm, randomised, double-blind, placebo-controlled trial, we will recruit children aged 3-18 years diagnosed with a FAPD during a routine health facility assessment and in whom other significant gastrointestinal disorders have been excluded. After an initial 2-week observation phase, eligible children will be randomised 1:1 to receive Enterosgel® or a matching placebo drink twice daily for 4 weeks during the double-blind treatment phase, then all children will receive open-label Enterosgel® treatment for a further 4 weeks. With support from parents/carers, children will record abdominal pain daily using the Wong-Baker FACES Pain Rating Scale. The primary outcome is change in mean daily pain score during the initial observation phase and the double-blind phase in the Enterosgel® versus the placebo arm. Secondary outcomes include change in gastrointestinal symptoms (assessed PedsQL™ 3.0 GIS module) and quality of life (KIDSCREEN-27) recorded at baseline and 6 and 10 weeks. After the initial clinical assessment, all procedures will be conducted remotely with study interventions sent by post.Discussion
In the absence of a currently available effective treatment, this study will assess the acceptability, efficacy and safety of Enterosgel® in the treatment of children and young people with FAPDs.Trial registration
ISRCTN ISRCTN16474818. Registered on 21 May 2025, https://www.isrctn.com/ISRCTN16474818.
Related
- Comparison of Postoperative Analgesic Efficacy Between Opioid-free Anaesthesia Using Intravenous Magnesium, Lidocaine, and Erector Spinae Plane Block, and Opioid-based Anaesthesia in Laparoscopic Abdominal Surgeries: A Randomised Controlled Trial
- Efficacy of Tuina on pain, functional activity, muscle strength and brain activity for patients with knee osteoarthritis in Shanghai: a randomised controlled trial protocol
- Multicentre randomised controlled trial to evaluate the efficacy of DIALIVE 2.0, a liver dialysis device, for the treatment of acute-on-chronic liver failure: study protocol
- Dietary Enhancement for Iron Deficiency and Anaemia Treatment (DEFeAT): study protocol for a randomised controlled trial to assess the effect of a mineral-enriched powder on iron deficiency in women of reproductive age
- Optimised blended treatment for alcohol use disorder (OptiBlend) in Dutch outpatient addiction care: study protocol for a three-arm randomised controlled trial
BibTeX
@article{howell2026randomised,
title = {{Randomised, placebo-controlled study to assess the safety and efficacy of Enterosgel® in the treatment of functional abdominal pain in children and young people (ENTOPIC): study protocol for a clinical trial.}},
author = {Carol A Howell and Manjula Velayudhan Nair and Marcus Karl-Heinz Auth and Christine Spray and Dharamveer Basude and Matthew Dodd and Elena Markaryan and Radovan Hnatič and Stephen J Allen},
journal = {Trials},
year = {2026},
month = jul,
doi = {10.1186/s13063-026-09913-y},
url = {https://europepmc.org/article/MED/42902396},
note = {CC BY-NC-ND},
}
RIS
TY - JOUR
TI - Randomised, placebo-controlled study to assess the safety and efficacy of Enterosgel® in the treatment of functional abdominal pain in children and young people (ENTOPIC): study protocol for a clinical trial.
AU - Carol A Howell
AU - Manjula Velayudhan Nair
AU - Marcus Karl-Heinz Auth
AU - Christine Spray
AU - Dharamveer Basude
AU - Matthew Dodd
AU - Elena Markaryan
AU - Radovan Hnatič
AU - Stephen J Allen
PY - 2026
DA - 2026/07/01
JO - Trials
DO - 10.1186/s13063-026-09913-y
UR - https://europepmc.org/article/MED/42902396
AB - Background Functional abdominal pain disorders (FAPDs) comprise of irritable bowel syndrome, functional dyspepsia, abdominal migraine and functional abdominal pain not otherwise specified. FAPDs are common in children worldwide, decrease health related quality of life, reduce attendance and participation in school and after-school activities similar to children with inflammatory bowel disease, and incur significant health care costs. The aetiology is thought to involve structural and/or functional disruptions in one or more elements of the microbiota-gut-brain axis. Several different treatment approaches are available, reflecting that none is proven to have significant efficacy. The medical device Enterosgel®, a silicon-based intestinal absorbent, adsorbs immune proteins, bacterial breakdown products and bile acids and normalises the intestinal microbiota. Enterosgel® is effective in irritable bowel syndrome with diarrhoea in adults and is available on prescription and over-the-counter. We plan to evaluate the efficacy, tolerability and safety of Enterosgel® in the treatment FAPDs in children and young people.Methods In a UK two-centre, parallel arm, randomised, double-blind, placebo-controlled trial, we will recruit children aged 3-18 years diagnosed with a FAPD during a routine health facility assessment and in whom other significant gastrointestinal disorders have been excluded. After an initial 2-week observation phase, eligible children will be randomised 1:1 to receive Enterosgel® or a matching placebo drink twice daily for 4 weeks during the double-blind treatment phase, then all children will receive open-label Enterosgel® treatment for a further 4 weeks. With support from parents/carers, children will record abdominal pain daily using the Wong-Baker FACES Pain Rating Scale. The primary outcome is change in mean daily pain score during the initial observation phase and the double-blind phase in the Enterosgel® versus the placebo arm. Secondary outcomes include change in gastrointestinal symptoms (assessed PedsQL™ 3.0 GIS module) and quality of life (KIDSCREEN-27) recorded at baseline and 6 and 10 weeks. After the initial clinical assessment, all procedures will be conducted remotely with study interventions sent by post.Discussion In the absence of a currently available effective treatment, this study will assess the acceptability, efficacy and safety of Enterosgel® in the treatment of children and young people with FAPDs.Trial registration ISRCTN ISRCTN16474818. Registered on 21 May 2025, https://www.isrctn.com/ISRCTN16474818.
SN - 1745-6215
ER -